Pharmaceutical Technology

MAY 22, 2023

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted an investigational new drug application (IND) for SinoMab BioScience’s SM17 to treat asthma. SinoMab BioScience intends to commence a Phase I clinical trial in China to evaluate SM17’s safety profile.

Immunity 109

Immunity Immunization Drug Development 109

The Pharmacist

SEPTEMBER 13, 2023

A PCN in Cumbria will implement an app that talks to patients to assist them in optimising their own medicine use at home without requiring additional clinical time. Eden PCN, which supports 54,000 patients, will deploy the Aide app to help improve management of long-term conditions, including asthma, type 2 diabetes and hypertension.

Diabetes 112

Diabetes 112

Pharmacy Times

SEPTEMBER 29, 2023

A workgroup of asthma treatment experts introduced 6 new criteria that those diagnosed with asthma must meet to be in remission.

52

52

Pharmaceutical Technology

APRIL 26, 2023

AstraZeneca , Teva Pharmaceuticals , and Novartis , and other companies, are expanding their reach in the asthma space by capitalizing on digital technologies to enhance the patient experience. Digital inhalers empower patients to be more proactive in taking control of their asthma,” says Mosnaim.

Medication Delivery 115

Medication Delivery Communication Drug Development 115

Pharmacy Is Right For Me

JANUARY 3, 2024

Linda Gutierrez-Miller, one such student, embarked on a journey to answer these questions, ultimately choosing a career path that aligns with her goals of making a substantial impact and aiding a diverse range of individuals—clinical pharmacy. However, job opportunities opened up that provided me with valuable clinical experience.

Diabetes 306

Diabetes Communication 306

Pharmaceutical Technology

JANUARY 8, 2023

In 2023, the pharmaceutical industry will mark 20 years since Xolair, an anti-IgE antibody, became the first biologic approved to treat asthma. Since then, the US FDA, EMA, and other agencies have approved several biologic antibodies targeting the inflammatory cytokines IL-4, IL-13, IL-5, and others for asthma.

119

119

pharmaphorum

SEPTEMBER 21, 2022

The European Commission has followed the lead of the US FDA and approved AstraZeneca’s Tezspire as an add-on maintenance therapy for patients with severe asthma, becoming the first and only biologic that can be used in all patients, and not restricted to those with specific forms of the disease. billion or more.

Labelling 109

Labelling 109

pharmaphorum

AUGUST 10, 2021

Oxford University and UK clinical artificial intelligence (AI) company Sensyne Health will partner on a project to find new drug targets for people with hard-to-treat asthma. According to Hinks, “we still don’t understand the causes of asthma, because in the past the scientific tools just didn’t exist.

Hospitals 113

Hospitals 113

STAT

NOVEMBER 7, 2023

In draft guidance published late last week, the National Institute for Health and Care Excellence stated that a groundbreaking treatment called Trikafta and two other cystic fibrosis medications sold by the company offer notable clinical benefits, but are not cost-effective.

Communication 237

Communication 237

Express Pharma

JUNE 18, 2023

Alkem Laboratories has launched the “Stop Sneeze to Wheeze” awareness initiative on World Allergy Week to raise awareness about the coexistence of allergic rhinitis and asthma – One Airway, One Disease.

97

97

pharmaphorum

MARCH 30, 2022

Data from a massive real-world study of asthma patients has suggested that overuse of inhalers is widespread and leading to an elevated risk of severe exacerbations. The finding was independent of the use of maintenance therapy with inhaled corticosteroids (ICS), used to dampen down the inflammation seen in the lungs of people with asthma.

113

113

European Pharmaceutical Review

AUGUST 8, 2023

Tom Keith-Roach, President of AstraZeneca UK announced: “We are pleased that the SMC has now accepted Forxiga (dapagliflozin) for use in patients with chronic heart failure with preserved or mildly reduced ejection fraction and Tezspire (tezepelumab) has been accepted for restricted use in severe asthma within NHS Scotland.”

88

88

Pharmacy Times

MARCH 15, 2024

The study showed no clinical differences for remission or asthma at age 28 years based on lung function, body mass index, daily smoking, exposure to parental tobacco smoke, or house dampness.

52

52

Outsourcing Pharma

NOVEMBER 15, 2021

The firm is investigating viability of voriconazole inhalation powder, intended to treat and prevent invasive pulmonary aspergillosis in asthma patients.

52

52

pharmaphorum

AUGUST 12, 2022

Patient recruitment specialist Clariness will deploy an app aimed at helping asthma patients monitor environment triggers and report symptoms in the clinical trials its support, thanks to a partnership with digital health firm DailyBreath.

52

52

Pharmafile

MARCH 23, 2023

Published date: 23/03/2023 Summary: • Symbicort Turbohaler 200/6 is the first and only approved dual-combination, inhaled corticosteroid + long-acting beta2-agonist (ICS/LABA) reliever therapy (Symbicort Reliever Therapy) to be taken as needed, in response to symptoms in patients with mild asthma aged 12 years and older.0F[1],1F[2],2F[3]

52

52

Pharmaceutical Technology

JUNE 9, 2023

Clinical-stage biotech company Upstream Bio has raised $200m in a Series B financing round to advance its UPB-101 to treat allergic and inflammatory diseases. Upstream Bio will use the funds to advance its UPB-101 into Phase II trials to treat asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).

59

59

pharmaphorum

JANUARY 12, 2023

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). An estimated 136 million asthma exacerbations occur globally each year, 10 million of those in the US.

52

52

Outsourcing Pharma

JANUARY 13, 2023

The US Food and Drug Administration (FDA) has approved AstraZenecaâs asthma treatment, Airsupra after positive results from a global phase 3 clinical trial.

59

59

Big Molecule Watch

APRIL 17, 2023

On April 10, 2023, Celltrion confirmed the bioequivalence of CT-P39 to treat allergic asthma and chronic urticaria, through its interim results from its global phase 3 clinical trials at 24 weeks.

Biosimilars 62

Biosimilars 62

Pharmaceutical Business Review

JANUARY 17, 2024

The development programme for Dupixent has highlighted its significant clinical benefit and its role in decreasing type 2 inflammation in multiple related diseases. Additionally, 52% of Dupixent-treated patients saw a clinically meaningful reduction in itch on hands and feet, compared to 14% who received placebo.

Labelling 103

Labelling 103

Outsourcing Pharma

JANUARY 16, 2023

A Florida doctor has been sent to prison after submitting a false affidavit claiming she had screened children in a clinical study looking at the effectiveness of drugs given to children with asthma when she had not.

59

59

pharmaphorum

NOVEMBER 16, 2022

There’s plenty in the pipeline to entice a potential buyer, however, including several mid-stage clinical candidates, such as EPO inhibitor LKA651 for diabetic retinopathy, Factor B inhibitor iptacopan for AMD, and gene therapy PPY988 for geographic atrophy. Novartis has said it will not comment on market speculation.

Biosimilars 123

Biosimilars Diabetes 123

European Pharmaceutical Review

NOVEMBER 21, 2023

If successful this could lead to regulatory submissions in 2025, supporting the health of asthma and COPD patients and making a significant positive impact on our transition to a more environmentally sustainable future,” GSK’s Chief Executive Officer, Emma Walmsley commented.

111

111

PharmaShots

MARCH 29, 2023

asthma The recommendation was based on the (PATHFINDER) program incl. Shots: The NICE has issued final draft guidance recommending Tezspire for use within NHS England and NHS Wales as an add-on maintenance therapy in adult and adolescent patients aged ≥12yrs. vs 1.73 & improvements in 2EPs over baseline, incl.

45

45

pharmaphorum

MAY 16, 2022

An albuterol/budesonide fixed-dose combination rescue medication has been shown to reduce severe exacerbations in patients with asthma for the first time, according to positive Phase 3 trial results announced by AstraZeneca and Avillion. Asthma affects as many as 339 million adults and children around the world.

70

70

Pharmaceutical Technology

NOVEMBER 18, 2023

Rilzabrutinib is under clinical development by Principia Biopharma and currently in Phase II for Asthma.

40

40

pharmaphorum

SEPTEMBER 17, 2021

Amgen and AstraZeneca haven’t won approval or announced a price for their severe asthma therapy tezepelumab should it reach the market, but ICER in the US maintains it will probably not be cost-effective.

52

52

pharmaphorum

FEBRUARY 26, 2021

AstraZeneca says full data from the NAVIGATOR trial of tezepelumab in severe asthma keep it on course to file for approval in the first half of this year, with a broader indication than rival biologic drugs. . There was also a clinically meaningful reduction in 39% of the <150 cells/µL group.

67

67

RX Note

APRIL 2, 2024

Introduction Contrast allergy is an immunologic and clinical reaction appearing hours to days after administration of iodinated or gadolinium-based contrast media. Due to the modest increased risk, restricting contrast medium use or premedicating solely on the basis of a history of asthma is not recommended.

52

52

pharmaphorum

NOVEMBER 9, 2022

AstraZeneca has moved a step closer to bringing a first-in-class drug to market in the US that can be used to reduce severe asthma attacks, after an FDA advisory committee voted in favour of approval. The post FDA panel backs AZ’s PT027 asthma rescue drug, but in adults only appeared first on.

Labelling 57

Labelling 57

Pharmaceutical Business Review

MARCH 14, 2023

The application to China National Medical Products Administration has been submitted based on positive data from Phase III trial undertaken on patients in China and the global SEA development programme, which included three important clinical trials – DREAM 2, MENSA3 and SIRIUS4.

52

52

Pharmaceutical Technology

FEBRUARY 24, 2023

Amlitelimab is under clinical development by Kymab and currently in Phase II for Asthma. According to GlobalData, Phase II drugs for Asthma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. It is administered through intravenous and subcutaneous routes as an infusion.

Immunity 40

Immunity Immunization Drug Development 40

pharmaphorum

DECEMBER 23, 2020

AstraZeneca and Amgen looked on course to cruise to approval of their severe asthma drug tezepelumab with a pair of positive clinical trials, but the failure of a third threatens to derail the programme. The post AZ, Amgen’s asthma hope tezepelumab flunks phase 3 trial appeared first on. billion in annual sales.

52

52

Pharmafile

JANUARY 11, 2023

Summary: • Airsupra is the first and only rescue medication approved in the US for as-needed use to reduce risk of asthma exacerbations. Approval based on successful Phase III trial programme conducted by Avillion in more than 4,000 patients under an exclusive clinical co-development agreement with AstraZeneca. read more.

Drug Development 40

Drug Development 40

Med Ed 101

OCTOBER 31, 2021

In clinical practice, I don’t see biologics in asthma very often, but it is something that I think is important to remember. According to the GINA guidelines, patients that have difficult to treat asthma and have been diagnosed with Type […].

40

40

pharmaphorum

DECEMBER 20, 2021

The FDA has approved AstraZeneca and Amgen’s severe asthma hope tezepelumab, exonerating the drugmakers’ decision to press ahead with a regulatory filing despite a failed phase 3 trial. billion at peak, given the pressing need for new treatment options for patients with severe non-eosinophilic asthma.

Hospitals 52

Hospitals 52